NCT00232999View on ClinicalTrials.gov

Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

January 31, 2006

Conditions
Asthma
Interventions
DRUG

Nebulized IVX-0142

Trial Locations (3)

L8N 3Z5

Department of Medicine, McMaster University, Hamilton

G1V 4G5

Centre de cardiology et de pneumologie de l'Universite Laval, Sainte-Foy (Quebec City)

S7N 0W8

University of Saskatchewan, Saskatoon

All Listed Sponsors
collaborator

AllerGen NCE Inc.

INDUSTRY

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00232999 - Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma | Biotech Hunter | Biotech Hunter